Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 411
- Registration Number
- NCT05069545
- Locations
- 🇧🇪
HUB - Hôpital Erasme, Bruxelles, Belgium
🇧🇪Imeldaziekenhuis - Bonheiden - Department of Endocrinology, Bonheiden, Belgium
🇧🇪Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie, Bruxelles, Belgium
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 407
- Registration Number
- NCT05064735
- Locations
- 🇺🇸
PrimeCare Medical Group, Houston, Texas, United States
🇨🇦Premier Clinical Trial Research Network (PCTRN), Hamilton, Ontario, Canada
🇺🇸Baptist Health System, Montgomery, Alabama, United States
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 267
- Registration Number
- NCT05053139
- Locations
- 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸Univ of Colorado Sch of Med, Aurora, Colorado, United States
🇺🇸Univ of Miami/SCCC, Miami, Florida, United States
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT05046873
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 207
- Registration Number
- NCT05040971
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦C-endo Diab Endo Clin Calgery, Calgary, Alberta, Canada
🇨🇦LMC Clin Res Inc. Thornhill, Concord, Ontario, Canada
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1262
- Registration Number
- NCT05035082
- Locations
- 🇺🇸
Scripps Whittier Diabetes Inst, La Jolla, California, United States
🇺🇸Baylor Scott & White Res Inst, Dallas, Texas, United States
🇺🇸FDRC, Costa Mesa, California, United States
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 667
- Registration Number
- NCT05035095
- Locations
- 🇺🇸
East West Med Res Inst, Honolulu, Hawaii, United States
🇫🇷Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu-2, Le Creusot, France
🇩🇪InnoDiab Forschung GmbH, Essen, Germany
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6200
- Registration Number
- NCT05021835
- Locations
- 🇺🇸
Renal Disease Research Institute, Dallas, Texas, United States
🇺🇸Biopharma Informatic_Houston, Houston, Texas, United States
🇺🇸Prolato Clinical Research Center, Houston, Texas, United States
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 672
- Registration Number
- NCT05016882
- Locations
- 🇺🇸
UF Hlth Jacksonville, Jacksonville, Florida, United States
🇩🇰Hvidovre Hospital - Gastroenheden, Hvidovre, Denmark
🇺🇸North AL Health Res, LLC, Huntsville, Alabama, United States
A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT05015894
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany